Collegium Reports 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Janney Capital Starts Collegium Pharmaceutical (COLL) at Buy
March 15, 2016 6:49 AM EDTJanney Capital initiated coverage on Collegium Pharmaceutical (NASDAQ: COLL) with a Buy rating and a price target of $25.00.
For an analyst ratings summary and ratings history on Collegium Pharmaceutical click here. For more ratings news on Collegium Pharmaceutical click here.
Shares of Collegium Pharmaceutical closed at $17.83 yesterday.
... MoreCollegium Pharma (COLL) Misses Q4 EPS by 1c
March 15, 2016 6:13 AM EDTCollegium Pharma (Nasdaq: COLL) reported Q4 EPS of ($0.46), $0.01 worse than the analyst estimate of ($0.45).
Financial Outlook
Based on our current operating plans, Collegium expects that its existing cash resources, along with the net proceeds of its January 2016 follow-on offering, will fund... More
